BSEBoard Meeting22h ago · 30 Jul 2026, 11:47 am
We have attached herewith outcome of Board Meeting to consider and approve the Financial Results for the quarter ended June 30, 2026. Kindly take the same on your record. Thank you.
Anlon Healthcare Ltd · 544497
✦ AI SummaryResults
Anlon Healthcare Ltd has announced the outcome of its Board Meeting, where the Board considered and approved the unaudited financial results for the quarter ended June 30, 2026, and also authorized the Chairman & Managing Director and/or Whole Time Director to enter into a share swap arrangement with the shareholders of Apiqo Organics Private Limited and Bizotic LifeScience Private Limited.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Anlon Healthcare Ltd - 544497 - Board Meeting Outcome for Financial Results For The Quarter Ended June 30, 2026
Attachments (1)
📄pdf
Download →
b26e5d8e-1a33-4181-b98c-eb0159d85a23.pdf
View document text
anion
July 30, 2026
To, To,
Listing Department, The National Stock Exchange of India
BSE Limited Ltd.
Phiroze Jeejeebhoy Towers, The Listing Department
Dalal Street, Exchange Plaza,
Mumbai - 400 001 Bandra — Kurla Complex,
Ref: BSE Scrip Code: 544497 Mumbai - 400051,
NSE Scrip Code: AHCL
Sub: Outcome of Board Meeting of ANLON HEALTHCARE LIMITED (“Company”)
Respected Sir/Madam,
Pursuant to Regulation 30 read with Part - A of Schedule III of SEBI Listing Regulations,
we wish to inform you that the Board of Directors of the Company at its meeting held
today i.e., Thursday, July 30, 2026 at the Registered Office of the Company inter alia
considered and approved the following matters:
1. Unaudited Financial Results (Standalone and Consolidated) of the Company as set
out in compliance with Indian Accounting Standards ("IND AS") for the quarter
ended June 30, 2026; together with the Limited Review Report of the Auditor's
thereon. (Enclosed herewith)
the Board authorized to Mr. Punitkumar Rasadia, Chairman & Managing Director
and/or Mr. Meet Vachhani, Whole Time Director of the Company, for entering into
a share swap arrangement with the shareholders of Apiqo Organics Private Limited
(“AOPL”) and Bizotic LifeScience Private Limited (“BLPL”) to acquire [32.52%]
shareholding in AOPL and [43.33%] shareholding in BLPL, to make both these
entities as wholly owned subsidiaries, in lieu of issuance and allotment of the fresh
equity shares of the Company on a preferential basis for consideration other than
cash, to such selling shareholders.
Meeting Commenced on 10:30 a.m. IST and Concluded on 11:30 a.m. IST.
You are requested to take the above information on your record.
Thanking You.
For ANLON HEALTHCARE LIMITED
PUNITKUMAR RASADIA
MANAGING DIRECTOR
DIN: 06696258
ANLON HEALTHCARE LIMITED
CIN No.: U24230GJ2013PLC077543
REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-
360005, Gujarat (INDIA)
PHONE NO.: +91-706969010/882 | Email: info@anlonhealthcare.com | www.anlon.in
&Co.
I Ren sd ue lp te sn de ofn t theA ud Ci oto mr p' as nyR evi pe uw r suR ae np to rt t o on R egth ue l aQ tu ia or nt er 3l 3 y ofa nd t he Yea Sr E BIto d (a Lt ie s tiU nn ga ud Oi bt le id ga tS it ona sn dal ano dn e DF ii sn ca ln oc si ua rl e
Requirements) Regulations, 2015, as amended
Review Report to
The Board of Directors
Anton Healthcare Limited
(1) W He
lth ha cv ae
re Lv ii me iw te ed
(t th he
'a Cc oc mo pm ap na yn ’y )i n fg
ts ht ea t qe um ae rn tt
o ef ndu en da u Jd ui nt ee d 30,s ta 2n 0d 2a 6l o an ne
yf ei an ra nc ti oa l
atr ee su fl rt os
o Af
riA ln to 01n
026 to June 30, 2026 (the Statement’), attached herewith, being submitted by the Company pursuant to
the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, as amended (the ‘Listing Regulations’).
(2) T C p p t 3h r r 3o hi i e ems n s rp o c c e fa i r upn iS tnly b ht de eea ' es dt s r e L m il u a se aB n tnn io d iddt a n e, gr r o d d t o h Rw S ew eh o e r gnf ci u tc laiDh acoi i tcnnr i oe oc uis nit n 1n so 3 td .r 3t iis h na,e g On o f u h rr pa A te rs hcs i rep c n eo cob sn iCe u ps pe on oi ln nmtb e si pi s il n ap bi gr n igt e li ey p ine a teS sr yrt o e aaf d ln A i l sd c ytt a ti h ,rn oe d a e ca 2 xcc 0C pec 13o rp4 3om e t,r sp e d s(a da I a n n sny ac d i n ' e a c s m oIA nneSw d cni i ldtM a uh e a 3 sd4n a i) ,t n oa ,h d neg e r‘ iem r oI na ne ne d tc c n eo o tt rg hw mi e n i pm i t l ht Sia i tn aFo ad r nin t en c ela e menaa evcnp a nid wp n ta ir tl t o m hv b e r ae a uR R sd les e ee pu g dsor u rb le ty oi am i ns tn e s ign ut oo’ eh t un, de r
review.
(3) (W E p m r ar mnSe e i ne e atR r ds s v ti E f ps tit o)c y eo t e c’ rnro a w
ss m tn
i ed 2 i sb imu 4 s tsl
e1 sc ht e
anu0 ht s tue, e te u d e. bd f
so r r t' itb A e glaR y o v n
ye fu i tr ti vr t ie e n i h aaw v dee ln
i r ow elcee
i yI w sv t a n oi ilso de t f lo enw i ef oo nt a s
tbu snI i
t t dno e n fa tf
i iti e n
een a r ao drt ci f bh i s m ce lm c m o iC
o nuo h pS fF nda e ait i uter nn sna irt aat tne a nn ae h tgr t c uc oam ie e di ne a id a omln
.a t a ttaA ni ats c An ieI sc ci nrf ann uo cs o uf r ou , dro aa i
rn mr n tc
dt am c a c
ia t na eo
nn i cdt rr go t oi ad lns no na aa
dn s cpn
u ec p c o co lfe t tn P wyo s tee eiI hi d r nn aw swd g tfi t di h ot s oa e ih r . wnat m eno nhe f aaT ot e d tlhh cr cye mi c ots a o eui kb xrcS lty i pdas dht rne l a ta
ga nn t sbn cd h a sde S ea en a itr
dnr ad
aqI d t nw mun oe ii ed t tmo r ar h hen ie ue e p en dq r ase itu S, wR tn i t ae rd r a reev e p oni evs rni s pd ii ite aem
w t f r owa ih r fdr oa eA sit e nu aplE .d ly r n lwi o oog et nf c sa oo e A ifrg d p u gm e ul ndpa ram ie ito n e fe ref t isn s r i c.oiat at n nans h ngld se tA
(4) tB Cl p oh aa froe i s i d m ne Rp cad ead i gc po n uc lo w i lo en n ae s m
s po
au g oir en n
A ny c er ti t rh 3e ,n e a
v g li l e 2 oa y f0w p S 1 pt 3 tl a hac ,i c
to c c e an em Lb ad pse ilu t sn ec e tt t da i, e m
Id gen i n ndp i dr Ra a Ie es en n p d gd aa u, irb la Ae ,o ac dv tc r e iheo, oaaui s ndn n
n t ,no a i w ot c n tih c
tgi no h dn
r ig ld S s ura t c den lh a ila c on nes e sd gv e a a dc r n tw tdo hi sm t et h e h er
u( l a"t it eI no h nsn e nd f o eou i rrr Ar se m S sc a’ ua i)o t net g i dt n o e wsi nn hpt t te iii hc croo ei henn f r q i e uet u iia tdh n rna edd it sd e u r tnc m oda t e oeu a a brs en bs e eds u S dr d iee ou sics m t cst he li cet oo lno r sn o t e s b dep ae ,d1rl c 3ii c3 oe n o i rv nc u e i o n t tfp t he l ait r th te n m a hs g st e i t
contains any material misstatement.
Date: July 30, 2026
For, RV D & Co
Place: Rajkot
Chartered Acc oun tants
ICAI Fir m istration No 143936W
hip No 174550 Yom
:2 Z| 2455 oF WYOOU HHA.
“Level-6",Office No 604-605,Near AP Park, Opp Imperial Heights, Rajkot-360005
+916356 797 885 & 0281 - 2991685 BSA office@cakda.iin @ www-cakdain
Anlon Healthcare Limited
L24230GJ2013PLC077543
Address: 101/102-Silver Coin Complex, Opp. Crystal Mall, Kalawad Road,Rajkot 360005, Gujarat (INDIA)
Standalone Financial Result for the period ended on 30-6-2026
Rs. in Lakhs (Unless stated otherwise)
Quarter Ended Year Ended
SrNo Particulars 30-6-2026 31-3-2026 30-6-2025 31 March 2026
Unaudited Audited
Revenue From Operations 3,097.56 5,542.22 3,329.72 17,649.87
Other Income 5.96 25 1.17 25.39
Total Income (I) 3,103.52 5,543.47 3,330.89 17,675.26
ll |Expenses
Cost of materials consumed 2,694.05. 3,323.68 2,959.48 12,976.38
Changes in inventories of finished goods, Stock in Trade and work in -789.16 235.76 -537.18 -1,691.69
Employee benefits expense 152.07 125.16 122.49 525.12
Finance costs 96.36 118.29 82.05 435.29
Depreciation and amortization expense 65.79 13.09 42.68 136.31
Other expenses 294.04 466.34 160.96 1,226.28
Total expenses (II) 2,513.15 4,282.32 2,830.48 13,607.69
Ill |Profit/(loss) before tax (I-Il) 590.37 1,261.15 500.41 4,067.57
IV |Tax expenses
Current tax 152.39 148.54 147.91 1,140.03
Deferred tax -41.73 133.41 -2.19 146.72
Total Tax expense (IV) 110.66 281.95 145.72 1,286.75
V_ |Profit/(loss) after tax for the period (IlI-IV) 479.71 979.20 354.69 2,780.82
VI |Other Comprehensive Income
OCI that will not be reclassified to P&L -2.31 -7.13 - -6.79
OCI Income tax of items that will not be reclassified to P&L 0.58 1.70 - 1.70
Total Other Comprehensive Income (VI) -1.73 -5.43 - -5.09
Vil. |Total Comprehensive Income for the period (V+VI) 477.98 973.77 354.69 2,775.73
Vill |Earnings per equity share
Basic 0.09 0.21 0.09 0.59
Diluted 0.09 0.21 0.09 0.59
For and on behalf of Board of Directors,
Anion Healthcare oY.
Place: Rajkot ;
Date: July 30, 2026
SIGNED FOR |DENTIFICATJON BY
RVD&Co,
Chartered Accountants
FRN 143936W
Date. 3@../2A./.2RPZE
Place : Rajkot
Anion Healthcare Limited
L24230GJ2013PLC077543
Notes to the Standalone Financial Result for the period ended on 30-6-2026
C A Pno hlr aop rno m r aa ct eHe ue ta ili ctn h
[Showing first 8,000 characters — download PDF for full document]